Navigation Links
Sunlight, Vitamin D May Cut Kids' Diabetes Risk
Date:6/5/2008

Type 1 disease less prevalent in populations living nearer equator, study finds

THURSDAY, June 5 (HealthDay News) -- Adequate sun exposure and vitamin D levels may play an important role in helping to prevent type 1 diabetes in children, a new study suggests.

Researchers at the University of California, San Diego, analyzed type 1 diabetes incidence rates and found that populations living at or near the equator -- where there is abundant sunshine -- have lower rates of the disease than populations at higher latitudes, where there is less sunlight.

Sunlight exposure causes the skin to produce vitamin D, which is also available through food and supplements.

"This is the first study, to our knowledge, to show that higher serum levels of vitamin D are associated with reduced incidence rates of type 1 diabetes worldwide," Cedric F. Garland, professor of family and preventive medicine, said in a prepared statement.

"The research suggests that childhood type 1 diabetes may be preventable with a modest intake of vitamin D3 (1,000 IU/day), ideally with five to 10 minutes of sunlight around noontime, when good weather allows," Garland said.

"Infants less than a year old should not be given more than 400 IU per day without consulting a doctor. Hats and dark glasses are a good idea to wear when in the sun at any age, and can be used if the child will tolerate them," he advised.

The study was published online Thursday in the journal Diabetologia.

Garland and his colleagues called for public health action to reduce widespread vitamin D inadequacy in U.S. children.

"This study presents strong epidemiological evidence to suggest that we may be able to prevent new cases of type 1 diabetes. By preventing this disease, we would prevent its many devastating consequences," Garland said.

Type 1 diabetes is the second most common chronic childhood disease, behind asthma.
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Study shines more light on benefit of vitamin D in fighting cancer
2. Vitamin Es lack of heart benefit linked to dosage
3. Fat transforms vitamin C from good cop into bad cop
4. Vitamin C Plus Fat Might Spur Cancer
5. How vitamin C stops the big C
6. Vitamin D Supplements May Lengthen Life
7. Joint Juice Launches New Ready-to-Drink Glucosamine & Vitamin-Enhanced Dietary Supplement Water Nationwide
8. Vitamin Relief Brings Needed Nutrition to School District Resurrecting After Katrina
9. Excessive Multivitamin Use May Raise Risk for Prostate Cancer, from Harvard Mens Health Watch
10. As Winter Approaches, Risk for Vitamin D Deficiency Increases
11. Vitamin D Wont Help Prevent Most Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 1SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 2SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 3SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 4Studying cancer in pet dogs to find new treatments for human patients 59325 1Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 1Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 3Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 4Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 5Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 6Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 7Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 8